Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03547297 · ClinicalTrials.gov registry record
INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
A clinical trial, sponsored by Alnylam Pharmaceuticals.
- Terminated
- Registry status
- 212
- Enrollment target
NCT03547297 is a clinical trial that was terminated before completion, run by Alnylam Pharmaceuticals. The registered enrollment target is 212 participants.
The verdict
NCT03547297 was terminated before completion, sponsored by Alnylam Pharmaceuticals.
- TERMINATED
- Registry status
- 212 participants
- Enrollment target
Study Summary
This study will use specific diagnostic tests on a group of patients who are experiencing symptoms typical of acute hepatic porphyria (AHP) to determine how many have the condition, and to potentially help improve the diagnostic process for patients in the future.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2018-05-29 |
| Est. Completion | 2019-01-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03547297
The ClinicalTrials.gov registry entry for NCT03547297 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03547297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03547297 about?
NCT03547297 is a clinical study titled "INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP". This study will use specific diagnostic tests on a group of patients who are experiencing symptoms typical of acute hepatic porphyria (AHP) to determine how many have the condition, and to potentially help improve the diagnostic process for patients in the future.
What is the current status of trial NCT03547297?
This trial is currently terminated. The enrollment target is 212 participants. The study started on 2018-05-29. Estimated completion is 2019-01-15.
Who is sponsoring clinical trial NCT03547297?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.